448 related articles for article (PubMed ID: 27856634)
1. Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody.
Zhang D; Goldberg MV; Chiu ML
J Biol Chem; 2016 Dec; 291(53):27134-27146. PubMed ID: 27856634
[TBL] [Abstract][Full Text] [Related]
2. Functional optimization of agonistic antibodies to OX40 receptor with novel Fc mutations to promote antibody multimerization.
Zhang D; Armstrong AA; Tam SH; McCarthy SG; Luo J; Gilliland GL; Chiu ML
MAbs; 2017 Oct; 9(7):1129-1142. PubMed ID: 28758875
[TBL] [Abstract][Full Text] [Related]
3. FcγRII-binding Centyrins mediate agonism and antibody-dependent cellular phagocytosis when fused to an anti-OX40 antibody.
Zhang D; Whitaker B; Derebe MG; Chiu ML
MAbs; 2018 Apr; 10(3):463-475. PubMed ID: 29359992
[TBL] [Abstract][Full Text] [Related]
4. An Fc engineering approach that modulates antibody-dependent cytokine release without altering cell-killing functions.
Kinder M; Greenplate AR; Strohl WR; Jordan RE; Brezski RJ
MAbs; 2015; 7(3):494-504. PubMed ID: 25933349
[TBL] [Abstract][Full Text] [Related]
5. An engineered Fc variant of an IgG eliminates all immune effector functions via structural perturbations.
Vafa O; Gilliland GL; Brezski RJ; Strake B; Wilkinson T; Lacy ER; Scallon B; Teplyakov A; Malia TJ; Strohl WR
Methods; 2014 Jan; 65(1):114-26. PubMed ID: 23872058
[TBL] [Abstract][Full Text] [Related]
6. The "less-is-more" in therapeutic antibodies: Afucosylated anti-cancer antibodies with enhanced antibody-dependent cellular cytotoxicity.
Pereira NA; Chan KF; Lin PC; Song Z
MAbs; 2018 Jul; 10(5):693-711. PubMed ID: 29733746
[TBL] [Abstract][Full Text] [Related]
7. Asymmetrical Fc engineering greatly enhances antibody-dependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies.
Liu Z; Gunasekaran K; Wang W; Razinkov V; Sekirov L; Leng E; Sweet H; Foltz I; Howard M; Rousseau AM; Kozlosky C; Fanslow W; Yan W
J Biol Chem; 2014 Feb; 289(6):3571-90. PubMed ID: 24311787
[TBL] [Abstract][Full Text] [Related]
8. Engineered antibody Fc variant with selectively enhanced FcγRIIb binding over both FcγRIIa(R131) and FcγRIIa(H131).
Mimoto F; Katada H; Kadono S; Igawa T; Kuramochi T; Muraoka M; Wada Y; Haraya K; Miyazaki T; Hattori K
Protein Eng Des Sel; 2013 Oct; 26(10):589-98. PubMed ID: 23744091
[TBL] [Abstract][Full Text] [Related]
9. IgG2m4, an engineered antibody isotype with reduced Fc function.
An Z; Forrest G; Moore R; Cukan M; Haytko P; Huang L; Vitelli S; Zhao JZ; Lu P; Hua J; Gibson CR; Harvey BR; Montgomery D; Zaller D; Wang F; Strohl W
MAbs; 2009; 1(6):572-9. PubMed ID: 20073128
[TBL] [Abstract][Full Text] [Related]
10. FcγRIIB engagement drives agonistic activity of Fc-engineered αOX40 antibody to stimulate human tumor-infiltrating T cells.
Campos Carrascosa L; van Beek AA; de Ruiter V; Doukas M; Wei J; Fisher TS; Ching K; Yang W; van Loon K; Boor PPC; Rakké YS; Noordam L; Doornebosch P; Grünhagen D; Verhoef K; Polak WG; IJzermans JNM; Ni I; Yeung YA; Salek-Ardakani S; Sprengers D; Kwekkeboom J
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32900860
[TBL] [Abstract][Full Text] [Related]
11. A general Fc engineering platform for the next generation of antibody therapeutics.
Chen D; Zhao Y; Li M; Shang H; Li N; Li F; Wang W; Wang Y; Jin R; Liu S; Li X; Gao S; Tian Y; Li R; Li H; Zhang Y; Du M; Cao Y; Zhang Y; Li X; Huang Y; Hu LA; Li F; Zhang H
Theranostics; 2021; 11(4):1901-1917. PubMed ID: 33408788
[No Abstract] [Full Text] [Related]
12. Optimal combination of beneficial mutations for improved ADCC effector function of aglycosylated antibodies.
Yoon HW; Jo M; Ko S; Kwon HS; Lim CS; Ko BJ; Lee JC; Jung ST
Mol Immunol; 2019 Oct; 114():62-71. PubMed ID: 31336250
[TBL] [Abstract][Full Text] [Related]
13. Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
Repp R; Kellner C; Muskulus A; Staudinger M; Nodehi SM; Glorius P; Akramiene D; Dechant M; Fey GH; van Berkel PH; van de Winkel JG; Parren PW; Valerius T; Gramatzki M; Peipp M
J Immunol Methods; 2011 Oct; 373(1-2):67-78. PubMed ID: 21855548
[TBL] [Abstract][Full Text] [Related]
14. An Engineered Human Fc variant With Exquisite Selectivity for FcγRIIIa
Kang TH; Lee CH; Delidakis G; Jung J; Richard-Le Goff O; Lee J; Kim JE; Charab W; Bruhns P; Georgiou G
Front Immunol; 2019; 10():562. PubMed ID: 30984171
[TBL] [Abstract][Full Text] [Related]
15. Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs.
Mimoto F; Kadono S; Katada H; Igawa T; Kamikawa T; Hattori K
Mol Immunol; 2014 Mar; 58(1):132-8. PubMed ID: 24334029
[TBL] [Abstract][Full Text] [Related]
16. Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein.
Oberst MD; Augé C; Morris C; Kentner S; Mulgrew K; McGlinchey K; Hair J; Hanabuchi S; Du Q; Damschroder M; Feng H; Eck S; Buss N; de Haan L; Pierce AJ; Park H; Sylwester A; Axthelm MK; Picker L; Morris NP; Weinberg A; Hammond SA
Mol Cancer Ther; 2018 May; 17(5):1024-1038. PubMed ID: 29545330
[TBL] [Abstract][Full Text] [Related]
17. Role of crosslinking for agonistic CD40 monoclonal antibodies as immune therapy of cancer.
Richman LP; Vonderheide RH
Cancer Immunol Res; 2014 Jan; 2(1):19-26. PubMed ID: 24416732
[TBL] [Abstract][Full Text] [Related]
18. Multi-Angle Effector Function Analysis of Human Monoclonal IgG Glycovariants.
Dashivets T; Thomann M; Rueger P; Knaupp A; Buchner J; Schlothauer T
PLoS One; 2015; 10(12):e0143520. PubMed ID: 26657484
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivo.
Li B; Xu L; Tao F; Xie K; Wu Z; Li Y; Li J; Chen K; Pi C; Mendelsohn A; Larrick JW; Gu H; Fang J
Oncotarget; 2017 Jun; 8(24):39356-39366. PubMed ID: 28454118
[TBL] [Abstract][Full Text] [Related]
20. Increasing FcγRIIa affinity of an FcγRIII-optimized anti-EGFR antibody restores neutrophil-mediated cytotoxicity.
Derer S; Glorius P; Schlaeth M; Lohse S; Klausz K; Muchhal U; Desjarlais JR; Humpe A; Valerius T; Peipp M
MAbs; 2014; 6(2):409-21. PubMed ID: 24492248
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
